Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 mg » 2 mm (Expand Search), 5 mg (Expand Search), _ mg (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 mg » 2 mm (Expand Search), 5 mg (Expand Search), _ mg (Expand Search)
-
1241
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”
-
1242
Serum concentrations of FGF23 at baseline and at week 40 in patients that achieved a serum phosphate concentration of <4.5 mg/dL and >4.5 mg/dL).
Published 2018“…Bars represent median and interquartile range. Serum iFGF23 decreased from 581.0 pg/mL (491.2–886.0) to 238.5 pg/mL (116.7–443.5) [median percent change of 63.8% (-75.2–5.40) in patients that achieved the target of phosphate <4.5 mg/dL. …”
-
1243
-
1244
-
1245
-
1246
-
1247
Table_1_A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit.pdf
Published 2022“…In multivariable analysis, even after excluding the confounding factors, such as age, APECHII score, pre-ECMO lactate, and incidence of CRRT during ECMO, the intervention bundle still can decrease the mortality independently, which also remained true in the statistical analysis of V-V and V-A ECMO separately. …”
-
1248
-
1249
-
1250
-
1251
-
1252
-
1253
-
1254
-
1255
-
1256
Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation.
Published 2025Subjects: -
1257
Analysis of apoptotic cells within the vocal fold muscle following DFATs transplantation.
Published 2025Subjects: -
1258
Effect of DFATs transplantation on collagen accumulation within the atrophic vocal fold muscle.
Published 2025Subjects: -
1259
-
1260